CompletedPhase 2

Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days

United States66 participantsStarted 2015-09

Plain-language summary

Evaluate the safety, tolerability, and efficacy of 28 days of treatment with ALLN-177 for reducing urinary oxalate excretion in patients with secondary hyperoxaluria and kidney stones.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * History of enteric or idiopathic hyperoxaluria or kidney stones * Urinary oxalate ≥ 50 mg/24 hours Exclusion Criteria: * Hyperuricosuria * Glomerular filtration rate \< 45 mL/min/1.73m2 * Hypercalcemia or hyperthyroidism * Autoimmune disorder requiring systemic steroids * Acute renal colic, primary hyperoxaluria, pure uric acid and/or cysteine stones, renal tubular acidosis, chronic urinary tract infection, or acute renal failure

What they're measuring

Mean change in urinary oxalate excretion (mg/24h)

Timeframe: 28 days

Trial details

NCT IDNCT02547805

SponsorAllena Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2017-01

View on ClinicalTrials.gov More Secondary Hyperoxaluria trials